CCL2 and glioma: Systemic CCL2 blockade with anti-CCL2 antibodies (Ab) resulted in decreased TAMs and MDSCs as well as modestly prolonged survival both in mice bearing intracranial GL261 glioma or intracranial human U87 glioma xenografts.